MI
MIST.US Milestone Pharmaceuticals Inc
- Market cap
- USD 64.7M
- P/E
- -
- P/B
- 3.55x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MIST.US undervalued?
Graham numberThe Graham number of Milestone Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Milestone Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Milestone Pharmaceuticals Inc yet.
Milestone Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate …
Full company profileMilestone Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Milestone Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 15.0M | 15.0M | 5.00M | 1.00M | 0.00 | 1.55M | 5.01M |
| Gross Profit | -8.00K | -10.0K | -236K | -376K | 15.0M | 5.00M | 1.00M | -646K | 1.43M | 4.44M |
| Operating Income | -8.27M | -23.8M | -57.9M | -50.7M | -43.1M | -59.6M | -61.1M | -42.1M | -62.5M | -99.3M |
| EBITDA | -8.26M | -23.4M | -57.8M | -50.6M | -42.5M | -59.6M | -57.0M | -37.8M | -59.5M | -92.5M |
| Net Income | -8.09M | -23.2M | -55.2M | -50.0M | -42.9M | -57.1M | -59.7M | -41.5M | -63.1M | -107M |
| EPS | -0.34 | -0.98 | -3.50 | -1.70 | -1.02 | -1.35 | -1.39 | -0.67 | -0.75 | -0.76 |
| Balance Sheet | ||||||||||
| Total Assets | 27.6M | 88.1M | 123M | 150M | 120M | 74.5M | 75.2M | 75.5M | 114M | 163M |
| Total Liabilities | 60.7M | 143M | 8.51M | 6.86M | 7.25M | 8.14M | 58.5M | 62.4M | 71.8M | 169M |
| Shareholders' Equity | -33.1M | -55.2M | 115M | 143M | 113M | 66.3M | 16.8M | 13.1M | 41.8M | -6.22M |
| Cash & Short-term Investments | 26.9M | 86.0M | 120M | 142M | 114M | 64.6M | 66.0M | 69.7M | 106M | 145M |
| Total Debt | - | - | 514K | 941K | 698K | 2.49M | 51.8M | 54.8M | 58.4M | 60.9M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -8.05M | -21.0M | -51.2M | -50.7M | -33.2M | -52.5M | -46.4M | -28.8M | -49.0M | -85.1M |
| Capital Expenditure | 36.0K | 5.00K | 413K | 97.0K | 0.00 | 272K | 112K | 33.0K | 302K | 99.6K |
| Free Cash Flow | -8.09M | -21.1M | -51.6M | -50.7M | -33.2M | -52.7M | -46.5M | -28.9M | -49.3M | -85.1M |
| Ratios | ||||||||||
| ROE | - | - | -48.1% | -34.9% | -38.1% | -86.1% | -355.9% | -315.8% | -151.0% | - |
| ROA | -29.3% | -26.3% | -44.7% | -33.3% | -35.8% | -76.7% | -79.3% | -55.0% | -55.5% | -66.0% |
| Net Profit Margin | - | - | - | -333.1% | -285.7% | -1,142.7% | -5,968.5% | - | -4,078.8% | -2,140.3% |
| Debt to Equity | - | - | 0.00x | 0.01x | 0.01x | 0.04x | 3.09x | 4.17x | 1.40x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Milestone Pharmaceuticals Inc dividends
Milestone Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Milestone Pharmaceuticals Inc
- Insiders 0.83%
- Institutions 52.78%
- Public & others 46.40%
- Shares outstanding 124M
- Free float 106M
Top funds holding MIST.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Simplify Propel Opportunities ETF | 3.35M | 2.69% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 27.4K | 0.02% | 0.00% | Oct 2026 |
Top institutions holding MIST.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Pavaki Capital Management LLC | 9.34M | 7.50% | +2.98% | Sep 2026 |
| RTW INVESTMENTS, LLC | 7.83M | 6.29% | +23.73% | Jun 2026 |
| Propel Bio Management LLC | 7.43M | 5.97% | +80.40% | Jun 2026 |
| Point72 Asset Management, L.P. | 5.41M | 4.35% | +398.41% | Jun 2026 |
| Simplify Asset Management Inc. | 3.35M | 2.69% | 0.00% | Sep 2026 |
| Millennium Management LLC | 3.14M | 2.52% | +103.47% | Jun 2026 |
| Kalehua Capital Management LLC | 2.54M | 2.04% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 2.04M | 1.64% | -11.96% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.80M | 1.44% | -7.55% | Jun 2026 |
| Lion Point Capital, LP | 820K | 0.66% | 0.00% | Jun 2026 |
| The Toronto-Dominion Bank | 750K | 0.60% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 667K | 0.54% | 0.00% | Jun 2026 |
| Boxer Capital Management, LLC | 667K | 0.54% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 635K | 0.51% | -12.28% | Jun 2026 |
| UBS Group AG | 465K | 0.37% | -5.96% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 463K | 0.37% | +174.30% | Jun 2026 |
| Susquehanna International Group, LLP | 360K | 0.29% | -30.66% | Jun 2026 |
| Aptus Capital Advisors, LLC | 339K | 0.27% | +21.12% | Jun 2026 |
| GUARDIAN WEALTH ADVISORS, LLC / NC | 339K | 0.27% | +21.12% | Jun 2026 |
| Seven Fleet Capital Management LP | 270K | 0.22% | -18.93% | Jun 2026 |
Milestone Pharmaceuticals Inc company profile
- Company name
- Milestone Pharmaceuticals Inc
- Ticker
- MIST.US
- ISIN
- CA59935V1076
- Exchange
- USA Stocks
- Listed since
- May 9, 2019
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 38
- Fiscal year end
- December
- Address
- 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
- Phone
- 514 336 0444
- Website
- milestonepharma.com
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc management
10- Mr. Joseph G. Oliveto M.B.A.CEO, President & Executive Director · born 1968
- Mr. Amit HasijaCFO & Executive VP of Corporate Development · born 1973
- Dr. David B. Bharucha FACC, M.D., Ph.D.Chief Medical Officer · born 1962
- Dr. Philippe Douville M.B.A., Ph.D.Founder, Strategic Advisor & Member of Scientific Advisory Board · born 1962
- Mr. Jeffrey NelsonChief Operating Officer · born 1981
- Mr. David SandovalGeneral Counsel & Chief Compliance Officer · born 1978
- Mr. Roshan GirglaniVice President of Marketing
- Mr. Jeff MooreVice President of Sales
- Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.Chief Medical Advisor & Member of the Scientific Advisory Board · born 1956
- Dr. Guy RousseauSVP of Regulatory Affairs and Quality Management